Mary Elizabeth Strek to Treatment Outcome
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Treatment Outcome.
Connection Strength
0.320
-
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
Score: 0.097
-
Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016 06; 47(6):1767-75.
Score: 0.055
-
Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016 Feb; 36:46-52.
Score: 0.054
-
Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc. 2010 May; 7(3):237-44.
Score: 0.036
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.019
-
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018 Dec 31; 27(150).
Score: 0.017
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.012
-
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18; 31(1):46-54.
Score: 0.012
-
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
Score: 0.011
-
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006 Jan; 129(1):56-66.
Score: 0.007